Limin Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Limin Shi has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Junxia Xie
Institute of Brain Science and Disease, Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders, Qingdao University, Qingdao 266071, China
8 shared publications Juntao Cui
Institute of Brain Science and Disease, Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders, Qingdao University, Qingdao 266071, China
6 shared publicationsJunliang Qian
Institute of Brain Science and Disease, Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders, Qingdao University, Qingdao 266071, China
5 shared publicationsLe Qu
Institute of Brain Science and Disease, Shandong Provincial Collaborative Innovation Center for Neurodegenerative Disorders, Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders, Qingdao University, Qingdao 266021, China
4 shared publicationsYanhong Liu
School of Basic Medicine, Institute of Brain Science and Disease, Shandong Key Laboratory of Pathogenesis and Prevention of Brain Diseases, Qingdao University, Qingdao, China
4 shared publicationsJing Zhang
School of Basic Medicine, Institute of Brain Science and Disease, Shandong Key Laboratory of Pathogenesis and Prevention of Brain Diseases, Qingdao University, Qingdao, China
3 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (18) , eaec6955
Piezoelectric neuromodulation of the subthalamic nucleus ameliorates motor and nonmotor symptoms of Parkinson’s disease
Traditional deep-brain stimulation via implanted electrodes can effectively treat neurological disorders, but surgical injury limits its clinical application. Here, we developed ultrasound-responsive piezoelectric nanoparticles for minimal-invasive and wireless neuromodulation. In the 6-OHDA–induced Parkinson’s disease (PD) mouse model, these nanoparticles are injected into the subthalamic nucleus (STN) of the mouse brain. After ultrasound stimulation for several days, the motor behavior, particularly gait abnormalities and nonmotor symptoms such as pain and anxiety, in PD mice is alleviated without detectable toxicity. The piezoelectric nanoparticles can activate the STN area of the mouse after ultrasound stimulation. Our results demonstrate that piezoelectric-mediated neuromodulation of the STN reverses motor deficits in PD by modulating neural signals, thereby protecting dopaminergic neurons and enhancing levels of the neurotransmitter dopamine. This process can rescue and mitigate mitochondrial dysfunction and neuroinflammation in the nigrostriatal pathway. Our approach enables STN neuronal activation with minimal invasiveness, offering a promising strategy for treating neurodegenerative diseases.
- 1 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (18) , eaec6955
Open AccessPiezoelectric neuromodulation of the subthalamic nucleus ameliorates motor and nonmotor symptoms of Parkinson’s disease
Traditional deep-brain stimulation via implanted electrodes can effectively treat neurological disorders, but surgical injury limits its clinical application. Here, we developed ultrasound-responsive piezoelectric nanoparticles for minimal-invasive and wireless neuromodulation. In the 6-OHDA–induced Parkinson’s disease (PD) mouse model, these nanoparticles are injected into the subthalamic nucleus (STN) of the mouse brain. After ultrasound stimulation for several days, the motor behavior, particularly gait abnormalities and nonmotor symptoms such as pain and anxiety, in PD mice is alleviated without detectable toxicity. The piezoelectric nanoparticles can activate the STN area of the mouse after ultrasound stimulation. Our results demonstrate that piezoelectric-mediated neuromodulation of the STN reverses motor deficits in PD by modulating neural signals, thereby protecting dopaminergic neurons and enhancing levels of the neurotransmitter dopamine. This process can rescue and mitigate mitochondrial dysfunction and neuroinflammation in the nigrostriatal pathway. Our approach enables STN neuronal activation with minimal invasiveness, offering a promising strategy for treating neurodegenerative diseases.
- 25 April 2026
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 265, 115712
Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson’s disease
- 25 April 2026
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 265, 115712
Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson’s disease
- Open Access
- 28 January 2026
- Published by Elsevier in Neurobiology of Disease
- Vol. 220, 107293
Inhibition of the LHb glutamatergic pathway ameliorates depressive-like behaviors in a 6-hydroxydopamine-induced Parkinson's disease mouse model
- 28 January 2026
- Published by Elsevier in Neurobiology of Disease
- Vol. 220, 107293
Open AccessInhibition of the LHb glutamatergic pathway ameliorates depressive-like behaviors in a 6-hydroxydopamine-induced Parkinson's disease mouse model
- Open Access
- 7 November 2025
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 26 (1) , 1-22
Activation of the zona incerta GABAergic circuit for the treatment of pain hypersensitivity in Parkinson’s disease mice model
Pain is a prevalent and frequently undertreated non-motor symptom in Parkinson’s disease (PD), affecting approximately 40% to 85% of patients. The zona incerta (ZI) is primarily an inhibitory subthalamic region involved in nociceptive neurotransmission. Previous studies demonstrated that the ZI is an important gamma-aminobutyric acid-ergic (GABAergic) source to the ventral tegmental area (VTA), but whether the ZI-VTA pathway participates in PD pain processing is still unclear. Given that deep brain stimulation targeting the ZI has demonstrated beneficial effects on pain perception in PD patients, we hypothesized that GABAergic signaling within the ZI may play a critical role in PD pain hypersensitivity. Male C57BL/6 mice and Vgat-Cre mice were used in the experiments. A unilateral PD mouse model was established through the injection of 6-hydroxydopamine (6-OHDA) into the striatum. We performed von Frey test and hot/cold plate tests to assess nociceptive behavior in PD mice. We then employed fiber photometry, chemogenetic, and optogenetic approaches to investigate the roles of ZI GABAergic neurons and ZIGABA-VTA circuit on PD pain hypersensitivity. Activation of ZI GABAergic neurons alleviated pain hypersensitivity in PD mouse model, whereas inhibition of these neurons was sufficient to induce pain hypersensitivity in control naïve mice. Furthermore, we demonstrated that projections from GABAergic neurons in the ZI to VTA are involved in regulating pain associated with PD. Chemogenetic and optogenetic activation of the ZIGABA-VTA circuit alleviated pain symptoms; conversely, inhibiting activity within this circuit exacerbated both mechanical and thermal pain hypersensitivity. Our results indicate that the ZI GABAergic neurons and their downstream projections to the VTA play crucial roles in modulating pain processing under both physiological conditions and during PD states. This research offers fresh perspectives on the PD pain mechanism. Considering our previous report indicating that stimulation of ZI GABAergic neurons improved motor performance in 6-OHDA-lesioned mice, we propose that the ZI may serve a dual regulatory function concerning both motor behavior and pain response associated with PD.
- 7 November 2025
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 26 (1) , 1-22
Open AccessActivation of the zona incerta GABAergic circuit for the treatment of pain hypersensitivity in Parkinson’s disease mice model
Pain is a prevalent and frequently undertreated non-motor symptom in Parkinson’s disease (PD), affecting approximately 40% to 85% of patients. The zona incerta (ZI) is primarily an inhibitory subthalamic region involved in nociceptive neurotransmission. Previous studies demonstrated that the ZI is an important gamma-aminobutyric acid-ergic (GABAergic) source to the ventral tegmental area (VTA), but whether the ZI-VTA pathway participates in PD pain processing is still unclear. Given that deep brain stimulation targeting the ZI has demonstrated beneficial effects on pain perception in PD patients, we hypothesized that GABAergic signaling within the ZI may play a critical role in PD pain hypersensitivity. Male C57BL/6 mice and Vgat-Cre mice were used in the experiments. A unilateral PD mouse model was established through the injection of 6-hydroxydopamine (6-OHDA) into the striatum. We performed von Frey test and hot/cold plate tests to assess nociceptive behavior in PD mice. We then employed fiber photometry, chemogenetic, and optogenetic approaches to investigate the roles of ZI GABAergic neurons and ZIGABA-VTA circuit on PD pain hypersensitivity. Activation of ZI GABAergic neurons alleviated pain hypersensitivity in PD mouse model, whereas inhibition of these neurons was sufficient to induce pain hypersensitivity in control naïve mice. Furthermore, we demonstrated that projections from GABAergic neurons in the ZI to VTA are involved in regulating pain associated with PD. Chemogenetic and optogenetic activation of the ZIGABA-VTA circuit alleviated pain symptoms; conversely, inhibiting activity within this circuit exacerbated both mechanical and thermal pain hypersensitivity. Our results indicate that the ZI GABAergic neurons and their downstream projections to the VTA play crucial roles in modulating pain processing under both physiological conditions and during PD states. This research offers fresh perspectives on the PD pain mechanism. Considering our previous report indicating that stimulation of ZI GABAergic neurons improved motor performance in 6-OHDA-lesioned mice, we propose that the ZI may serve a dual regulatory function concerning both motor behavior and pain response associated with PD.
- Open Access
- 5 August 2025
- Published by Elsevier in Neurobiology of Disease
- Vol. 214, 107049
Decoding the dual regulatory systems: Contemporary insights into the lateral habenula and rostromedial tegmental nucleus physiology
- 5 August 2025
- Published by Elsevier in Neurobiology of Disease
- Vol. 214, 107049
Open AccessDecoding the dual regulatory systems: Contemporary insights into the lateral habenula and rostromedial tegmental nucleus physiology
- 22 March 2025
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 132 (6) , 845-857
Abnormal iron metabolism in the zona incerta in Parkinson’s disease mice
Parkinson’s disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra (SN) and abnormal iron metabolism. While most of the current studies have focused on nigral iron deposition, there is still limited research into the role of iron in other brain regions. The zona incerta (ZI) is a heterogeneous subthalamic region and has extensive connections with the basal ganglia nucleus. Clinically, the ZI has been recognized as a new therapeutic target for PD. Deep brain stimulation of the ZI has been reported to relieve motor symptoms and experimental heat pain in patients with PD. The aim of the present study is to evaluate changes in iron levels in the ZI. Two neurotoxins, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA), were used to prepare PD mice. By immunostaining, we first measured the success of MPTP or 6-OHDA injury. We found that the expressions of tyrosine hydroxylase were decreased after MPTP or 6-OHDA treatment. Secondly, we observed the changes of iron metabolism using Perls’ iron staining and western blots. Our results showed that the numbers of iron-positive cells were significantly increased in the SN and ZI of MPTP/6-OHDA-treated mice. Moreover, the expression levels of ferritin and divalent metal transporter 1 (DMT1) in the ZI were also increased in the PD group. Glutathione peroxidase 4 (GPX4), a marker of ferroptosis, was also detected. Western blots revealed that MPTP significantly down-regulated the level of GPX4 in the ZI. As glial cells activation and neuroinflammation play important roles in the ion deposition, we finally investigated the microglial and astrocyte activation and inflammatory factors. These results suggested increased iron levels and inflammation may be present in the ZI in PD mice.
- 22 March 2025
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 132 (6) , 845-857
Abnormal iron metabolism in the zona incerta in Parkinson’s disease mice
Parkinson’s disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra (SN) and abnormal iron metabolism. While most of the current studies have focused on nigral iron deposition, there is still limited research into the role of iron in other brain regions. The zona incerta (ZI) is a heterogeneous subthalamic region and has extensive connections with the basal ganglia nucleus. Clinically, the ZI has been recognized as a new therapeutic target for PD. Deep brain stimulation of the ZI has been reported to relieve motor symptoms and experimental heat pain in patients with PD. The aim of the present study is to evaluate changes in iron levels in the ZI. Two neurotoxins, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA), were used to prepare PD mice. By immunostaining, we first measured the success of MPTP or 6-OHDA injury. We found that the expressions of tyrosine hydroxylase were decreased after MPTP or 6-OHDA treatment. Secondly, we observed the changes of iron metabolism using Perls’ iron staining and western blots. Our results showed that the numbers of iron-positive cells were significantly increased in the SN and ZI of MPTP/6-OHDA-treated mice. Moreover, the expression levels of ferritin and divalent metal transporter 1 (DMT1) in the ZI were also increased in the PD group. Glutathione peroxidase 4 (GPX4), a marker of ferroptosis, was also detected. Western blots revealed that MPTP significantly down-regulated the level of GPX4 in the ZI. As glial cells activation and neuroinflammation play important roles in the ion deposition, we finally investigated the microglial and astrocyte activation and inflammatory factors. These results suggested increased iron levels and inflammation may be present in the ZI in PD mice.
- 10 October 2024
- Published by Elsevier in Experimental Neurology
- Vol. 382, 114992
The zona incerta system: Involvement in Parkinson's disease
- 10 October 2024
- Published by Elsevier in Experimental Neurology
- Vol. 382, 114992
The zona incerta system: Involvement in Parkinson's disease
- 7 September 2023
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 208, 445-457
TFEB regulates cellular labile iron and prevents ferroptosis in a TfR1-dependent manner
- 7 September 2023
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 208, 445-457
TFEB regulates cellular labile iron and prevents ferroptosis in a TfR1-dependent manner